Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Ghady Haidar, S. Thomas, Paul Loubet, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Laura E. Rosen, M. Alejandra Tortorici, Anna De Marco, et al.
Cell (2024)
Open Access | Times Cited: 7
A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
Thomas Starkey, Maria C. Ionescu, Michaël Tilby, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 17
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
David A. Van Eijndhoven, Robin Vos, Saskia Bos
Transplant International (2025) Vol. 38
Open Access
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia
Ohad Benjamini, Tamar Tadmor, Abraham Avigdor, et al.
Acta Haematologica (2024) Vol. 147, Iss. 6, pp. 634-645
Open Access | Times Cited: 4
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19
Lindsay E. Clegg, Oleg Stepanov, Henning Schmidt, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 5
Open Access | Times Cited: 4
Management of vaccinations in patients with non‐Hodgkin lymphoma
Michele Merli, Andrea Costantini, Silvio Tafuri, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1617-1634
Open Access | Times Cited: 2
Assessing the post hoc effectiveness of tixagevimab−cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients
Stanley C. Jordan, Sandy Joung, Minhao Wang, et al.
Transplant Infectious Disease (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
Anais Romero, Charlotte Laurent, L Lebourg, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 381-381
Open Access | Times Cited: 1
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation
Marco Falcone, Giusy Tiseo, G. Marchetti, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-8
Closed Access | Times Cited: 1
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
Paul Loubet, Benjamin Gaborit, Mathilde Salpin, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study
Diego R. Hijano, Jose Ferrolino, Elizabeth Swift, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases
Nicola Sgherza, Paola Curci, Rita Rizzi, et al.
Annals of Hematology (2023) Vol. 103, Iss. 1, pp. 351-355
Closed Access | Times Cited: 3
Tixagevimab/cilgavimab for the prevention of COVID‐19 in solid organ transplant recipients
Emily Eribes, Cassandra Votruba, Tyler Tinkham, et al.
Clinical Transplantation (2024) Vol. 38, Iss. 2
Closed Access
Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder
Dominika Šťastná, Marta Vachová, Pavel Dušek, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 85, pp. 105523-105523
Closed Access
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study
Naokazu Nakamura, Hiroko Tsunemine, Ryo Ikunari, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 8, pp. 1117-1126
Closed Access
Increased Risk of Breakthrough SARS-CoV-2 Infections in Patients with Colorectal Cancer: A Population-Based Propensity-Matched Analysis
Saqr Alsakarneh, Fouad Jaber, Hana Qasim, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2495-2495
Open Access
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
Myron J. Levin, Andrew Ustianowski, Stéphane De Wit, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 6, pp. 1253-1268
Open Access
Clinical Characteristics and Patterns of Immune Responses in COVID-19 Patients From a Rural Community Hospital
Ninh M. La‐Beck, Young Rok Lee, Jalpa Patel, et al.
Cureus (2024)
Open Access
Carga de la COVID-19 variante ómicron en pacientes inmunocomprometidos en España: revisión sistemática
Raúl Ortiz-de-Lejarazu, Borja Quiroga, Alberto López García
Medicina Clínica (2024) Vol. 163, Iss. 7, pp. 347-359
Open Access
Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center
Keith Hamilton, Elvis Hua, Lauren Dutcher, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 8
Open Access
Burden of COVID-19 variant omicron in immunocompromised patients in Spain: Systematic review
Raúl Ortiz-de-Lejarazu, Borja Quiroga, Alberto López García
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 7, pp. 347-359
Closed Access
Phytonutrient Formulation Using Gum Arabic and Adansonia Digitata Pulp: Lessons for Boosting the Human Immune System - Part 1
Ahmed A. M. Elnour, Nour Hamid Abdurahman
Phytomedicine Plus (2024), pp. 100663-100663
Open Access
Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants—a prospective cohort study (RESCUE-TX)
Roman Reindl‐Schwaighofer, Andreas Heinzel, Lukas Raab, et al.
EBioMedicine (2024) Vol. 109, pp. 105417-105417
Open Access
Comprehensive procedure for injecting Evusheld® for hematological diseases in a single institute
Osamu Imataki, Shunsuke Yoshida, Tomoya Ishida, et al.
Annals of Hematology (2024)
Open Access
Page 1 - Next Page

Scroll to top